Ultragenyx Pharmaceutical
RARE
174 hedge funds and large institutions have $2.93B invested in Ultragenyx Pharmaceutical in 2016 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 63 increasing their positions, 61 reducing their positions, and 19 closing their positions.
101.88% more ownership
Funds ownership: 0% → 101.88% (+102%)
21% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 19
1% more funds holding
Funds holding: 172 → 174 (+2)
5% more capital invested
Capital invested by funds: $2.79B → $2.93B (+$135M)
3% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 61
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less call options, than puts
Call options by funds: $6.29M | Put options by funds: $6.65M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$79.6M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$36.9M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$28.5M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$14.8M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$21.3M |
| 2 |
IHM
Iguana Healthcare Management
New York
|
-$17M |
| 3 |
Goldman Sachs
New York
|
-$16.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11.2M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$11.2M |
RARE Hedge Fund Activity: Q4 2016 in Review
174 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2016, worth a combined $2.93B — up 4.8% from $2.79B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new RARE positions and 19 closed out — a net gain of 4 holders — while 63 added to existing stakes and 61 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $79.6M. The largest seller was BlackRock Advisors, cutting an estimated $21.3M.
- 174 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2016, up from 172 in Q3 2016.
- Funds reported $2.93B of Ultragenyx Pharmaceutical stock for Q4 2016, up 4.8% quarter-over-quarter.
- 23 funds opened new Ultragenyx Pharmaceutical positions in Q4 2016 and 19 closed out, a net change of +4 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q4 2016 was Wellington Management Group, an estimated $79.6M added.
- The largest Ultragenyx Pharmaceutical seller in Q4 2016 was BlackRock Advisors, an estimated $21.3M sold.
Based on aggregated 13F filings for Q4 2016.